PCSAライブシグナル | Getagraph.comで利益を最大化

買う 110661 min ago

@ $2.43

発行日: 13 2月 2024 @ 05:26

リターン: -7.82%

前回のシグナル: 2月 7 - 04:26

前回のシグナル: 売る

リターン: 0.00 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
本日の出来高	217 847
平均出来高	1.52M
時価総額	6.40M
EPS	$0 ( 2024-04-04 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.0130 (0.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.29
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

ボリューム相関

長: -0.04 (neutral)

短: -1.00 (very strong negative)

Signal:(55.794) Neutral

Processa Pharmaceuticals, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Processa Pharmaceuticals, 相関 - 通貨/商品

0.74
( moderate )

0.69
( moderate )

0.00
( neutral )

0.86
( strong )

0.45
( neutral )

0.01
( neutral )

Processa Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2023
収益:	$0
総利益:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2022
収益:	$0
総利益:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.